SEC Class Action Alert: Tenax Therapeutics Faces Legal Scrutiny from Shareholders Amid Major Losses

Tenax Therapeutics Faces Class Action Lawsuit



Levi & Korsinsky, LLP has announced that shareholders of Tenax Therapeutics, Inc. (NASDAQ: TENX) are being alerted to a pending securities class action lawsuit that highlights potential misleading statements issued by the company's executives. This lawsuit comes in response to a significant decline in the company's stock value following disappointing results from a clinical trial involving its drug, TNX-103.

On August 10, 2026, Tenax revealed that its Phase 3 LEVEL trial did not meet its primary endpoint, resulting in shares plummeting by nearly 90%. This abrupt decline has prompted investors to seek accountability, naming the company's CEO, Christopher T. Giordano, along with three successive Chief Financial Officers (CFOs) as defendants in the class action.

The lawsuit alleges that these individuals were responsible for controlling Tenax's public messaging over several years while the company raised around $134 million from investors. It claims that the executives had access to critical information that contradicted the rosy projections about TNX-103's effectiveness and potential. The plaintiffs argue that the company misled investors, leading to substantial financial losses.

Strategic Decisions of Tenax Executives



The complaint centers on the alleged failure of Tenax's leadership to disclose vital details about TNX-103 during its clinical trials. As the individual defendants are accused of creating and disseminating optimistic communications regarding the drug’s prospects, the class action seeks to hold them accountable under Section 20(a) of the Securities Exchange Act, which pertains to control person liability.

According to the lawsuit, Giordano and the CFOs either knew or should have known that the claims surrounding TNX-103 were not substantiated by clinical evidence. Investors who purchased shares between November 13, 2023, and August 7, 2026, may have the opportunity to recover their losses, and the deadline to apply as lead plaintiff is set for December 28, 2026.

Background of the Clinical Trial and Company Performance



The LEVEL trial's failure is a significant setback for Tenax, as it was anticipated to demonstrate the drug’s efficacy in improving the 6-minute walk distance when compared to a placebo. The unexpected results have raised questions about the management of the company's clinical directives and investor relations, fostering an environment conducive to legal action from affected shareholders.

Investors are urged to collect their brokerage records to substantiate their claims and are advised they do not need to go to court or provide testimony, as most class action members do not have to appear. Rather, they can submit claims for a potential recovery.

Legal Repercussions and Shareholder Rights



The class action, filed in the United States District Court for the Middle District of North Carolina, highlights the significant responsibility corporate officers have to ensure their companies' public statements are accurate. This lawsuit marks a critical moment for Tenax Therapeutics as they face increasing scrutiny not only from shareholders but also from regulatory bodies initiated by the dramatic downturn in stock performance.

Levi & Korsinsky, LLP, renowned for defending shareholders' rights, has emphasized that accountability is key when companies fail to meet their obligations relating to transparency and investor communication. This case could set a precedent for how mismanagement in public companies is addressed in the future, particularly regarding clinical trial disclosures.

For shareholders seeking to take action, contacting a legal representative promptly is advised. Investors can reach out to Levi & Korsinsky at (212) 363-7500 or via email at [email protected] for a no-cost evaluation of their eligibility to participate in the lawsuit.

Topics Financial Services & Investing)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.